FLSM
MAZE

Frazier Life Sciences Management’s Maze Therapeutics MAZE Stock Holding History

Frazier Life Sciences Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150M Buy
5,032,915
+465,641
+10% +$12.2M 3.27% 8
2026
Q1 		$136M Hold
4,567,274
– – 3.51% 8
2025
Q4 		$189M Hold
4,567,274
– – 5.08% 7
2025
Q3 		$118M Sell
4,567,274
-1
-0% -$17 3.55% 8
2025
Q2 		$56M Buy
4,567,275
+438,274
+11% +$4.56M 2.24% 12
2025
Q1 		$45.5M Buy
+4,129,001
New +$49.7M 2.08% 12

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Frazier Life Sciences Management's MAZE Position: Q2 2026 in Review

Frazier Life Sciences Management increased its Maze Therapeutics (MAZE) stake by 10% in Q2 2026, buying an estimated $12.2M and bringing the position to 5,032,915 shares worth $150M. The position accounts for 3.27% of the portfolio, ranked #8.

Frazier Life Sciences Management first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $189M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Frazier Life Sciences Management held 5,032,915 shares of Maze Therapeutics worth $150M as of Q2 2026.
  • Frazier Life Sciences Management bought 465,641 Maze Therapeutics shares in Q2 2026, an estimated $12.2M.
  • Maze Therapeutics made up 3.27% of Frazier Life Sciences Management's portfolio in Q2 2026, its #8 holding.
  • Frazier Life Sciences Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Frazier Life Sciences Management's Maze Therapeutics position peaked at $189M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.